Clinical Trials
21 trialsNCT05323734 2025-07-11
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Completed
NCT02849457 2024-08-19
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
University of Alabama at Birmingham
Phase 2 Completed
NCT04595513 2024-05-16
STOP2
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT01906866 2024-04-23
Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Neurim Pharmaceuticals Ltd.
Phase 3 Completed
NCT03826628 2023-09-08
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Dermatology Specialties Limited Partnership
Phase 2/3 Completed
NCT04285346 2023-04-04
TSC
Marinus Pharmaceuticals
Phase 2 Completed
NCT02544763 2022-09-28
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT02544750 2022-07-14
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT00126672 2022-04-25
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03525834 2021-09-09
Safety and Efficacy of Everolimus (AfinitorĀ®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT01526356 2020-10-26
Treatment
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT01289912 2018-01-25
TSC
Boston Children's Hospital
Phase 2 Completed
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00411619 2014-10-20
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed